Volume 7, Number 5—October 2001
Research
Clinical Consequences and Cost of Limiting Use of Vancomycin for Perioperative Prophylaxis: Example of Coronary Artery Bypass Surgery
Table 2
Strategy | Deep SSI | Increm. deep SSIa | Superficial SSI | Increm. superficial SSIa | Hospital deaths | Increm. hospital deathsa | Deaths, SSI, or both | Increm. deaths, SSI, or both | Costs (x $1,000) | Increm. costs (x $1,000)a |
---|---|---|---|---|---|---|---|---|---|---|
No prophylaxis | 570 | - | 1,141 | - | 405 | - | 2,008 | - | 33,410 | - |
Routine cefazolin | 397 | - 173‡ | 794 | - 347b | 391 | - 14b | 1,506 | - 502b | 24,530 | - 8,880b |
Routine vancomycin | 368 | - 29b | 736 | - 58b | 388 | - 3b | 1,423 | - 83b | 23,360 | - 1,170b |
SSI = surgical site infection; increm = incremental.
aRoutine cefazolin compared with no prophylaxis; routine vancomycin compared with routine cefazolin.
bNegative incremental numbers of infections or deaths represent the numbers of infections or deaths averted; negative incremental costs represent costsaving.
Page created: April 26, 2012
Page updated: April 26, 2012
Page reviewed: April 26, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.